Petros Pharmaceuticals, Inc. (PTPI) Earnings History
Annual and quarterly earnings data from 2018 to 2024
Loading earnings history...
PTPI EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
PTPI Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 76.3% | -345.8% | -280.1% |
| 2023 | 72.0% | -233.9% | -140.2% |
| 2022 | 61.8% | -332.4% | -334.4% |
| 2021 | 79.5% | -231.1% | -115.0% |
| 2020 | 57.7% | -180.8% | -215.3% |
Download Data
Export PTPI earnings history in CSV or JSON format
Free sign-in required to download data
Petros Pharmaceuticals, Inc. (PTPI) Earnings Overview
As of May 9, 2026, Petros Pharmaceuticals, Inc. (PTPI) reported trailing twelve-month net income of -$7M, reflecting +47.4% year-over-year growth. The company earned $-0.17 per diluted share over the past four quarters, with a net profit margin of -280.1%.
Looking at the long-term picture, PTPI's historical earnings data spans multiple years. The company achieved its highest annual net income of -$8M in fiscal 2023.
Petros Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRGO (-$1.82B net income, -33.5% margin), HIMS ($128M net income, 5.5% margin), MNKD (-$24M net income, 1.7% margin), PTPI has room to improve margins relative to the peer group. Compare PTPI vs PRGO →
PTPI Earnings vs Peers
Earnings metrics vs comparable public companies
PTPI Historical Earnings Data (2018–2024)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$14M | -75.4% | -$18M | $-3.34 | -280.1% | -345.8% |
| 2023 | -$8M | +59.3% | -$14M | $-6.35 | -140.2% | -233.9% |
| 2022 | -$20M | -123.0% | -$20M | $-9.68 | -334.4% | -332.4% |
| 2021 | -$9M | +56.3% | -$18M | $-8.25 | -115.0% | -231.1% |
| 2020 | -$21M | +36.7% | -$17M | $-38.55 | -215.3% | -180.8% |
| 2019 | -$33M | -0.1% | -$19M | $-132.16 | -208.7% | -124.0% |
| 2018 | -$32M | - | -$8M | $-324.73 | -231.1% | -54.4% |
See PTPI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PTPI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PTPI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPTPI — Frequently Asked Questions
Quick answers to the most common questions about buying PTPI stock.
Is PTPI growing earnings?
PTPI EPS is $-0.17, with earnings growth accelerating to +47.4%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-7M.
What are PTPI's profit margins?
Petros Pharmaceuticals, Inc. net margin is -280.1%, with operating margin at -345.8%. Below-average margins reflect competitive or cost pressures.
How consistent are PTPI's earnings?
PTPI earnings data spans 2018-2024. The accelerating earnings trend is +47.4% YoY. Historical data enables comparison across business cycles.